Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

BACKGROUND: With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study primarily aimed to describe the time to treatment fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Boegemann, Martin, Khaksar, Sara, Bera, Guillaume, Birtle, Alison, Dopchie, Catherine, Dourthe, Louis-Marie, Everaert, Els, Hatzinger, Martin, Hercher, Dirko, Hilgers, Werner, Matus, Geoffrey, Alvarez, Laura Garcia, Antoni, Laurent, Lukac, Martin, Pissart, Geneviève, Robinson, Paul, Elliott, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332550/
https://www.ncbi.nlm.nih.gov/pubmed/30642291
http://dx.doi.org/10.1186/s12885-019-5280-6

Ejemplares similares

Ejemplares similares